

SITAGLIPTIN HCl & SITAGLIPTIN HCl + Metformin

Blood Glucose
Lowering
Drug (DPP4-i)

Main indication

— Treatment of Type 2 Diabetes mellitus in adults.

Benefits of your dossier acquisition

- Secured production from patent expiry date
- Assured production capacity
- Vertically integrated product
- Reliable supply (more than one API supplier strategy)
- Available Marketing Authorization approvals

Your European Dossier

	SITAGLIPTIN HCl	SITAGLIPTIN HCl + METFORMIN
STRENGTHS	25 mg ● 50 mg ●● 100 mg ●●●	850 mg ●●●● 1000 mg ●●●●●
PH FORM	Film-coated tablets	Film-coated tablets
STABILITY DATA	Zone II Zone IVa: ◡◡b Zone IVb: on going	Zone II Zone IVa: ◡◡b Zone IVb: on going
SHELF-LIFE	36 months	24 months
PACK SIZES	14, 28, 56, 98 Al / PVC / PVDC blisters	14, 28, 56, 98, 196 Al/PVC/PVDC blisters & Al/OPA/Al/PVC blisters*

IVa: ◡b= Not available, can be extrapolated from IVb | *Zone IV




Multidisciplinary support for your launch effectiveness. **R&D, RA, QA, IP**

CONTACT US:

 FARMAPROJECTS

 sales@farmaprojects.com

 www.farmaprojects.com

Disclaimer: The above information is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.